New MGA Analysis of the Adalimumab Biosimilars Market in the United States

Feb 21, 2023 | Analysis, Press Releases

New MGA Analysis of the Adalimumab Biosimilars Market in the United States Below is the press release from Biosimilars Council regarding the new report from MGA examining biosimilar competition for Humira (adalimumab) in the US market. Washington, D.C. (February 21,...

Humira Rivals Set to Try to Drive Down Cost of Blockbuster Drug

Jan 31, 2023 | Interviews

Humira Rivals Set to Try to Drive Down Cost of Blockbuster Drug Celine Castronuovo | Bloomberg Law News “More than 1.4 million patients have used Humira globally, according to AbbVie. The drug takes up a huge chunk of Medicare spending in the US, with an HHS...

New MGA Analysis of Biosimilar Coverage in Commercial Medical Benefit

Dec 8, 2022 | Analysis

New MGA Analysis of Biosimilar Coverage in Commercial Medical Benefit A new MGA white paper from CEO Alex Brill and Principal Christy Robinson shows a positive outlook for biosimilar coverage in the commercial medical benefit. While patients and physicians play a role...

Q&A: Maura Keefe and Alex Brill Discuss Understanding Drug Rebates and Their Role in Promoting Competition

Aug 25, 2022 | Interviews

Q&A: Maura Keefe and Alex Brill Discuss Understanding Drug Rebates and Their Role in Promoting Competition Alex Brill, a senior fellow at the American Enterprise Institute and CEO of Matrix Global Advisors, recently sat down with CAPD spokesperson Maura Keefe to...

New PCMA Podcast Highlights Importance of Prescription Drug Rebates

Aug 16, 2022 | Press Releases

New PCMA Podcast Highlights Importance of Prescription Drug Rebates PCMA released the following press release regarding Alex Brill’s interview on the importance of prescription drug rebates. (Washington, D.C.) — The Pharmaceutical Care Management Association’s...